financetom
Business
financetom
/
Business
/
Ferragamo launches action plan after H1 loss
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ferragamo launches action plan after H1 loss
Jul 31, 2025 9:36 AM

(Reuters) -Italian luxury group Salvatore Ferragamo said it had put in place a plan to revive sales and relaunch its brand as it deals with eroding consumer demand and macroeconomic certainty.

The Florentine group, currently without a chief executive after the exit of Marco Gobbetti in March, posted a first-half adjusted net loss of 16 million euros ($18 million), against a net profit of 6 million euros in the same period of 2024.

The group said it had undertaken a review of its brands and identified key priorities and the development of a "focused action plan".

Ferragamo has already started implementing changes in the second quarter, it said, and believes these efforts will become increasingly effective by the end of the year, carrying into 2026.

Sales at constant exchange rates in the first six months of the year fell by 7.1% to 474 million euros, mainly dragged down by the wholesale channel and by weak consumer demand in the Asia Pacific region.

($1 = 0.8738 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Main Street Capital Prices $100 Million Debt Offering
Main Street Capital Prices $100 Million Debt Offering
Sep 12, 2024
04:00 AM EDT, 09/12/2024 (MT Newswires) -- Main Street Capital ( MAIN ) said late Wednesday it priced an underwritten public offering of $100 million in 6.50% notes due 2027 at a premium to par of 102.134% for expected gross proceeds of about $102.1 million. The offering is expected to close Friday. The notes are an extension of a $300...
Ascendis Pharma Gets FDA Orphan Drug Designation for Hypoparathyroidism Treatment
Ascendis Pharma Gets FDA Orphan Drug Designation for Hypoparathyroidism Treatment
Sep 12, 2024
05:02 AM EDT, 09/12/2024 (MT Newswires) -- Ascendis Pharma ( ASND ) said late Wednesday the US Food & Drug Administration has granted orphan drug designation to Yorvipath, providing seven years of market exclusivity in the US for the treatment of hypoparathyroidism in adults. Orphan drug designation provides drug developers with certain benefits and incentives, including the waiver of FDA...
Johnson & Johnson Secures FDA Approval for Tremfya as Ulcerative Colitis Treatment
Johnson & Johnson Secures FDA Approval for Tremfya as Ulcerative Colitis Treatment
Sep 12, 2024
05:07 AM EDT, 09/12/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Wednesday that the US Food and Drug Administration has approved Tremfya for the treatment of adults with moderately to severely active ulcerative colitis. The company said the approval is supported by data from the ongoing phase 2b/3 study evaluating Tremfya in adult patients with moderately to...
US holiday sales to grow at slowest pace since 2018, report says
US holiday sales to grow at slowest pace since 2018, report says
Sep 12, 2024
(Reuters) - U.S. holiday sales are expected to grow at their slowest pace in six years, data from Deloitte showed on Thursday as persistent inflation and dried up savings turn shoppers more frugal for the all-important shopping period. Holiday retail sales are likely to rise between 2.3% and 3.3% in the November 2024-January 2025 period, totaling up to $1.59 trillion,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved